Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy

R T Staff, H G Gemmell, M F Shanks, A D Murray, A Venneri

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Alzheimer's disease is associated with a loss in presynaptic cholinergic function. It has been suggested that cholinergic inhibitors such as donepezil hydrochloride (Donepezil) could restore this function and improve some of the symptoms of Alzheimer's disease. Previous work has shown that Donepezil improves cognitive and global function in patients with mild to moderate Alzheimer's disease. This study reviewed retrospectively 12 patients who had previously had a Tc-99(m)-hexamethylpropylene amine oxime (Tc-99(m)-HM PAO) single photon emission tomography (SPET) regional cerebral blood flow (rCBF) examination and had gone on to receive Donepezil therapy. These patients were recalled for a further Tc-99(m)-HMPAO SPET rCBF examination and the image data sets were compared. The results showed an overall increase in global cerebral blood flow (P = 0.04) averaged over the group with a percentage change in blond flow ranging from -1.8% to 6.4%. However, some patients showed a slight decrease in. blood flow. When the data were analysed in terms of regional cerebral blood flow, we found that the most significant increase in blood flow occurred in the frontal lobes (P = 0.02). ((C) 2000 Lippincott Williams & Wilkins).

Original languageEnglish
Pages (from-to)37-41
Number of pages5
JournalNuclear Medicine Communications
Volume21
Publication statusPublished - 2000

Cite this

Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy. / Staff, R T ; Gemmell, H G ; Shanks, M F ; Murray, A D ; Venneri, A .

In: Nuclear Medicine Communications, Vol. 21, 2000, p. 37-41.

Research output: Contribution to journalArticle

@article{8a0f3a971368453f869dbf916ea01bd1,
title = "Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy",
abstract = "Alzheimer's disease is associated with a loss in presynaptic cholinergic function. It has been suggested that cholinergic inhibitors such as donepezil hydrochloride (Donepezil) could restore this function and improve some of the symptoms of Alzheimer's disease. Previous work has shown that Donepezil improves cognitive and global function in patients with mild to moderate Alzheimer's disease. This study reviewed retrospectively 12 patients who had previously had a Tc-99(m)-hexamethylpropylene amine oxime (Tc-99(m)-HM PAO) single photon emission tomography (SPET) regional cerebral blood flow (rCBF) examination and had gone on to receive Donepezil therapy. These patients were recalled for a further Tc-99(m)-HMPAO SPET rCBF examination and the image data sets were compared. The results showed an overall increase in global cerebral blood flow (P = 0.04) averaged over the group with a percentage change in blond flow ranging from -1.8{\%} to 6.4{\%}. However, some patients showed a slight decrease in. blood flow. When the data were analysed in terms of regional cerebral blood flow, we found that the most significant increase in blood flow occurred in the frontal lobes (P = 0.02). ((C) 2000 Lippincott Williams & Wilkins).",
author = "Staff, {R T} and Gemmell, {H G} and Shanks, {M F} and Murray, {A D} and A Venneri",
year = "2000",
language = "English",
volume = "21",
pages = "37--41",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy

AU - Staff, R T

AU - Gemmell, H G

AU - Shanks, M F

AU - Murray, A D

AU - Venneri, A

PY - 2000

Y1 - 2000

N2 - Alzheimer's disease is associated with a loss in presynaptic cholinergic function. It has been suggested that cholinergic inhibitors such as donepezil hydrochloride (Donepezil) could restore this function and improve some of the symptoms of Alzheimer's disease. Previous work has shown that Donepezil improves cognitive and global function in patients with mild to moderate Alzheimer's disease. This study reviewed retrospectively 12 patients who had previously had a Tc-99(m)-hexamethylpropylene amine oxime (Tc-99(m)-HM PAO) single photon emission tomography (SPET) regional cerebral blood flow (rCBF) examination and had gone on to receive Donepezil therapy. These patients were recalled for a further Tc-99(m)-HMPAO SPET rCBF examination and the image data sets were compared. The results showed an overall increase in global cerebral blood flow (P = 0.04) averaged over the group with a percentage change in blond flow ranging from -1.8% to 6.4%. However, some patients showed a slight decrease in. blood flow. When the data were analysed in terms of regional cerebral blood flow, we found that the most significant increase in blood flow occurred in the frontal lobes (P = 0.02). ((C) 2000 Lippincott Williams & Wilkins).

AB - Alzheimer's disease is associated with a loss in presynaptic cholinergic function. It has been suggested that cholinergic inhibitors such as donepezil hydrochloride (Donepezil) could restore this function and improve some of the symptoms of Alzheimer's disease. Previous work has shown that Donepezil improves cognitive and global function in patients with mild to moderate Alzheimer's disease. This study reviewed retrospectively 12 patients who had previously had a Tc-99(m)-hexamethylpropylene amine oxime (Tc-99(m)-HM PAO) single photon emission tomography (SPET) regional cerebral blood flow (rCBF) examination and had gone on to receive Donepezil therapy. These patients were recalled for a further Tc-99(m)-HMPAO SPET rCBF examination and the image data sets were compared. The results showed an overall increase in global cerebral blood flow (P = 0.04) averaged over the group with a percentage change in blond flow ranging from -1.8% to 6.4%. However, some patients showed a slight decrease in. blood flow. When the data were analysed in terms of regional cerebral blood flow, we found that the most significant increase in blood flow occurred in the frontal lobes (P = 0.02). ((C) 2000 Lippincott Williams & Wilkins).

M3 - Article

VL - 21

SP - 37

EP - 41

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

ER -